Editing Biogen (section)

===Bioverativ===
In May 2016, the company announced that it would [[Corporate spin-off|spin off]] its hemophilia drug business ([[Eloctate]] and [[Alprolix]]) into a public company.<ref>{{cite news | url=https://www.reuters.com/article/us-biogen-hemophilia-idUSKCN0XU15E | title=Biogen to spin off hemophilia drug business into a public company | work=Reuters | date=May 3, 2016 | access-date=May 3, 2016 | author=D'Souza, Savio}}</ref> In August, the company announced that the spun off company would be called [[Bioverativ]], in order to show heritage with Biogen.<ref>{{cite web|url=http://www.fiercepharma.com/pharma/biogen-introduces-spinoff-bioverativ-amid-takeover-buzz|title=Amid takeover chatter, Biogen introduces hemophilia spinoff Bioverativ - FiercePharma|date=10 August 2016 }}</ref> The company would trade on the [[Nasdaq|NASDAQ]] exchange under the ticker symbol BIVV<ref>{{Cite press release|url=http://www.businesswire.com/news/financialpost/20160809005296/en/Biogen-Announces-Bioverativ-Hemophilia-Focused-Company|title=Biogen Announces Bioverativ as Name of New Hemophilia-Focused Company {{!}} Business Wire|website=Businesswire|language=en|access-date=2017-12-28}}</ref><ref>{{cite web|url=https://www.bostonglobe.com/business/2016/08/09/biogen-unveils-name-for-hemophilia-drug-spinoff-bioverativ/2EjLRgOOGpOZJECl3nO4yH/story.html|title=Biogen unveils name for hemophilia drug spinoff: Bioverativ |work=Boston Globe}}</ref> and would look to be spun off in early 2017.<ref>{{cite web|url=http://media.biogen.com/press-release/hemophilia-spin/biogen-announces-bioverativ-name-new-hemophilia-focused-company|title=Biogen Announces Bioverativ as Name of New Hemophilia-Focused Company - Biogen Media|access-date=2016-08-11|archive-url=https://web.archive.org/web/20160813045653/http://media.biogen.com/press-release/hemophilia-spin/biogen-announces-bioverativ-name-new-hemophilia-focused-company|archive-date=2016-08-13|url-status=dead}}</ref> Bioverativ was acquired by [[Sanofi]] in 2018 for about $11.6 billions<ref>{{cite web|url=https://www.globenewswire.com/news-release/2018/01/22/1298161/0/en/Sanofi-to-Acquire-Bioverativ-for-11-6-Billion.html|title=Sanofi to Acquire Bioverativ for $11.6 Billion|date=January 22, 2018|access-date=January 31, 2025|via=Sanofi|archive-url=https://archive.today/20250131210010/https://web.archive.org/web/20180123170819/https://www.globenewswire.com/news-release/2018/01/22/1298161/0/en/Sanofi-to-Acquire-Bioverativ-for-11-6-Billion.html|archive-date=January 31, 2025|url-status=live}}</ref><ref>{{cite web|author=Sudip Kar-Gupta|url=https://www.reuters.com/article/world/sanofi-digs-deep-to-buy-us-haemophilia-group-bioverativ-for-116-billion-idUSKBN1FB08C/|title=Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion|date=January 22, 2018|publisher=[[Reuters]]|access-date=January 31, 2025|archive-url=https://archive.today/20250131210455/https://www.reuters.com/article/world/sanofi-digs-deep-to-buy-us-haemophilia-group-bioverativ-for-116-billion-idUSKBN1FB08C/|archive-date=January 31, 2025|url-status=live}}</ref><ref>{{cite web|url=https://www.france24.com/en/20180122-sanofi-buys-us-haemophilia-treatment-firm-116-bn-0|title=Sanofi buys US haemophilia treatment firm for $11.6 bn|location=Paris|publisher=AFP|access-date=January 31, 2025|date=January 22, 2018|archive-url=https://archive.today/20250131211047/https://web.archive.org/web/20201109014437/https://www.france24.com/en/20180122-sanofi-buys-us-haemophilia-treatment-firm-116-bn-0|archive-date=January 31, 2025|url-status=live}}</ref> ($105 per share in cash).<ref>{{cite web|url=https://www.sec.gov/Archives/edgar/data/1121404/000119312518074806/d538875dex991.htm|title=Sanofi Completes Acquisition of Bioverativ Inc.- Bioverativ Inc. is a fully owned subsidiary of Sanofi|location=Paris|date=March 8, 2018|archive-url=https://archive.today/20250131210315/https://www.sec.gov/Archives/edgar/data/1121404/000119312518074806/d538875dex991.htm|archive-date=January 31, 2025|url-status=live}}</ref>